New Findings from START Study headed by DC CFAR Investigator Dr. Fred Gordin

Dr Fred Gordin, Executive Committee Member of the DC CFAR and Principal Investigator of the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) Clinical Trails Unit (CTU) at the Veterans Affairs Medical Center in Washington, DC, served as the Study Chair for the Strategic Timing of Antiretroviral Treatment (START) study funded by the National Institutes of Health (NIH). Recently released findings from this major international randomized clinical trial found that HIV-infected individuals have a substantially lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral (ARV) drugs sooner instead of waiting until their CD4+ cell count drops to lower levels. These findings, along with previous studies showing that ARV treatment reduces risk of HIV transmission to uninfected sexual partners, support offering treatment to everyone with HIV. To learn more, please see the press release.